180 related articles for article (PubMed ID: 16061002)
1. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
3. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
[TBL] [Abstract][Full Text] [Related]
4. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
5. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
6. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
7. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
[TBL] [Abstract][Full Text] [Related]
8. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
10. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study.
Bessant R; Duncan R; Ambler G; Swanton J; Isenberg DA; Gordon C; Rahman A
Arthritis Rheum; 2006 Dec; 55(6):892-9. PubMed ID: 17139666
[TBL] [Abstract][Full Text] [Related]
12. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.
Bernatsky S; Joseph L; Boivin JF; Gordon C; Urowitz M; Gladman D; Fortin PR; Ginzler E; Bae SC; Barr S; Edworthy S; Isenberg D; Rahman A; Petri M; Alarcón GS; Aranow C; Dooley MA; Rajan R; Sénécal JL; Zummer M; Manzi S; Ramsey-Goldman R; Clarke AE
Ann Rheum Dis; 2008 Jan; 67(1):74-9. PubMed ID: 17545189
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster in systemic lupus erythematosus.
Manzi S; Kuller LH; Kutzer J; Pazin GJ; Sinacore J; Medsger TA; Ramsey-Goldman R
J Rheumatol; 1995 Jul; 22(7):1254-8. PubMed ID: 7562754
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.
Akawatcharangura P; Taechakraichana N; Osiri M
Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
18. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
19. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure.
Shapiro CL; Phillips G; Van Poznak CH; Jackson R; Leboff MS; Woodard S; Lemeshow S
Breast Cancer Res Treat; 2005 Mar; 90(1):41-6. PubMed ID: 15770525
[TBL] [Abstract][Full Text] [Related]
20. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
Sinha R; Dionne JM
Arch Dis Child; 2008 May; 93(5):444-5. PubMed ID: 17908713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
